The H63D Trap: Why Homozygous HFE p.His63Asp was Declared Benign on the Endpoints of Hereditary Haemochromatosis

The HFE variant p.His63Asp (H63D) is common in European populations. Homozygosity is on the order ofabout 2%. Guidelines and population-based cohorts declare this genotype largely clinically benign. Thatstatement is internally consistent — but only if the endpoint is classical hereditary haemochromatosis (HH): ferritin, hepatic iron load, cirrhosis, HCC, diabetes, and cardiomyopathy in the HH sense. That is the trap. The biochemical signature of H63D homozygosity is not primarily hyperferritinaemia, but an increase in transferrin saturation (TfSat) with ferritin that is often normal or only modestly changed. NTBI arises at TfSat, not at ferritin. Population studies that define “clinical significance” by ferritin and HH organ endpoints can systematically miss TfSat-/NTBI-driven pathology. Extrahepatic association studies(Parkinson’s disease, Alzheimer’s disease, ALS) exist, but they are heterogeneous, mostly allele-based ratherthan restricted to homozygosity, and almost never measure NTBI. Conclusion: The claim that “H63D homozygosity is harmless in 97% of carriers” is a statement about HHpenetrance, not a statement about the entire phenotypic spectrum. H63D syndrome, as currently investigated, is not identical with the homozygosity. Homozygosity is the necessary genetic prerequisite; additional factors accrue (including NTBI burden, immunological and mitochondrial cofactors). The genotype alone does not yield the syndrome diagnosis. Conversely: declaring the homozygosity harmless on HH endpoints removes the prerequisite of syndrome research. Guidelines have not adopted H63D syndrome yet which is still under research; however, that does not change the fact that it exists as an object of research, and that the harmlessness formula closes the wrong door. What is needed is population-based phenotyping of H63D homozygotes with TfSat, a reproducible NTBI assay, neurological-autonomic status, and imaging of iron in the substantia nigra — not another ferritin follow-up.